Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on October 10, 2023. The registrant is a Delaware corporation with its principal executive offices in Irvine, CA. The company is classified as an emerging growth company and its common stock trades on The Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The material event reported is the receipt of a "Bid Price Notice" from the Nasdaq Staff. The Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This non-compliance is based on the closing bid price for the last 30 consecutive business days.
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial period of 180 calendar days to regain compliance.
- Compliance Criteria: To resolve the matter within the initial period, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days.
- Contingency Plan: If the Company fails to regain compliance within the initial 180 days but meets other listing standards, it may request an additional 180-day period. This extension is contingent on the Company's intention to cure the deficiency, potentially through a reverse stock split.
- Management Commentary: Management intends to actively monitor performance and consider available options, including a reverse stock split if necessary, to regain compliance.
Investor Verification Checklist
- Verify the current trading price of RSLS to assess the likelihood of meeting the $1.00 bid price requirement within 180 days.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Confirm the company's status regarding other Nasdaq listing requirements (e.g., market value of publicly held shares) to ensure eligibility for a second compliance period if needed.
- Note the discrepancy between the requested company name (Vyome Holdings, Inc.) and the actual registrant (ReShape Lifesciences Inc.).